Chronic graft-versus-host disease (GVHD) is a major limitation of successful allogeneic hematopoietic stem cell transplantation (HSCT).
substantial number of patients with both skin and visceral chronic GVHD failing corticosteroids and other immunosuppression.
Introduction
Chronic graft-versus-host disease (GVHD) is a major limitation of successful allogeneic HSCT, and it affects the majority of patients that develop acute GVHD [1, 2] . Chronic GVHD is a disease of deregulated immunity with protean manifestations similar in many ways to autoimmune diseases. The relative uncommonness of the disease, the lack of consensus on what represents true manifestations of chronic GVHD, the very limited understanding of its pathophysiology, and the clinical complexity of these patients are all factors that have hindered a systematic approach to this problem.
Chronic GVHD has a negative impact on the morbidity and quality of life, as well as in non-relapse mortality [2, 3] . Corticosteroids are considered the standard of care for initial treatment of chronic GVHD, but only a minority of patients durably responds to them. So far, there are more questions than answers regarding chronic GVHD. These patients are subject to long-term complications of corticosteroid treatment, and management of steroid resistant chronic GVHD is not well defined [4] . A variety of different immunosuppressive and immunomodulating modalities have been tested in chronic GVHD, among them extracorporeal photochemotherapy (ECP), or photopheresis. Photopheresis is currently indicated and FDA approved for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) which is a clonally derived skin malignancy of CD4+ cells with the phenotype of mature helper T-cells. CTCL responds to biological response modification [5] , and ECP produces a high clinical response rate [6] [7] [8] . It is felt that this therapy not only augments the function of monocytes but also induces the malignant Tcells to undergo a high rate of apoptosis, exerting an anti-tumor effect through cytokine modulation and modification [9, 10] .
In chronic GVHD, ECP has been tested quite extensively in small cohorts of patients, and responses were observed in skin, liver, GI tract, mouth, eye and lung [11] [12] [13] [14] [15] [16] . Unfortunately, the literature is difficult to interpret due to the heterogeneity of treatment schedules, diagnostic and response assessment criteria.
In this study, we evaluate the efficacy and safety of ECP in a group of patients with a clinical diagnosis of chronic GVHD failing corticosteroids and treated with similar ECP schedule.
Patients, Material and Methods

Patient Population
We evaluated a total of 246 patients who received systemic immunosuppression for the treatment of steroid refractory chronic GVHD between 1/98 and10/02. Of these, we analyzed all patients treated with ECP (n= 71) during this time period. Referral to ECP therapy was at the discretion of the primary transplant physician.
Results were presented for the whole group and separately for patients treated with K 3 versus > 3 lines of immunosuppression prior to initiation of ECP. Results and outcomes are presented for all patients. Considering that in patients receiving multiple lines of immunosuppression, it is impossible to discriminate the effects of each particular treatment, our analysis of outcomes and prognostic factors was focused on the 63 patients who had K 3 lines of immunosuppression including tacrolimus and steroids. 
Definition of chronic GVHD and Steroid Refractoriness
For the purpose of this analysis, we defined chronic GVHD based upon clinical manifestations and independently of the date of diagnosis. Thus, patients were considered to have chronic GVHD only if they had one or more of the characteristic chronic, long-standing manifestations of GVHD [2] , including lichenoid or sclerodermal skin Chronic GVHD was considered to be "de novo" if there was no prior history of acute GVHD. Relapsing chronic GVHD occurred if there For personal use only. on October 3, 2017. by guest www.bloodjournal.org From was a prior history of successfully treated acute GVHD. Progressive chronic GVHD was defined as acute GVHD which failed to completely respond to treatment and evolved into chronic GVHD. Patients were also classified as having limited or extensive chronic GVHD according to Sullivan et al [17] .
Patients in this analysis were initially treated for GVHD with a combination of tacrolimus and methylprednisolone starting at 1-2 mg/kg/day. Tacrolimus doses were adjusted to maintain trough levels of 5-15 ng/ml. Corticosteroids were generally continued until evidence of a clinical response and then tapered as tolerated. Chronic GVHD was considered refractory or resistant to therapy if: a) patients had stable disease (i.e. no response, NR) after one month of treatment, b) no more than a partial response (PR) occurred after two months of treatment, or c) progressive disease occurred after 2 weeks of initiation of steroid treatment or during the methylprednisolone taper.
These same criteria were used to define steroid refractoriness prior to inclusion in this retrospective study.
Chronic GVHD Response Criteria
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Complete remission (CR) was defined as resolution of all manifestations of chronic GVHD. Partial remission (PR) was defined as at least a 50% improvement of clinical manifestations without a CR.
In this case, due to the complexity inherent to the assessment of response in chronic GVHD, we defined PR for each organ as follows:
-Skin: For lichenoid rashes a minimum reduction in the body surface area involved by 50%. For sclerodermatous involvement, any improvement in the skin score or range of motion, with an improvement in Zubrod performance status by 1.
-Ocular GVHD: Subjective improvement and reduction in the frequency of artificial tear administration by 50%, or improvement in Schirmer's test for one or both eyes.
-Oral GVHD: Improvement by 50% in the mucosal area involved with lichenoid and/or ulcerative changes.
-GI and liver: Decrease by 50% in the volume of diarrhea, bilirrubin or alkaline phosphatase. The timing of the response was analyzed as: -Best response of at least 2 weeks duration, occurring within 3 months after initiation of therapy and -Response at 6 months following initiation of therapy.
Extracorporeal Photochemotherapy
ECP was performed both on an outpatient and inpatient basis.
Extracorporeal photopheresis (ECP) was performed using the UVAR TS machine (Therakos, Inc.) Whenever feasible six cycles were performed for each treatment using the 125 mL bowl. Liquid methoxsalen (UVADEX ) was injected into the recirculation bag of the ECP circuit after collection of the buffy coat was complete, but prior to the photoactivation process. The UVADEX dosage was All patients initiated therapy with 2-4 weekly treatments, and tapered when partial response was observed. Treatments were decreased by 1 per week when a partial response was observed, and subsequently the patients were placed on a maintenance regimen of 2 treatments every 2 weeks. Discontinuation and duration of treatment was at the discretion of the treating physician, titrating the ECP treatments to control of symptomatic manifestations of chronic GVHD.
Statistical Analysis
The main endpoints were response to therapy, non-relapse mortality and overall survival. The effects of patients' and clinical characteristics on response were evaluated using logistic regression analysis. The 
Results
Demographics
Patient characteristics are summarized in Table 1 Chronic cutaneous GVHD was the leading indication for ECP (n= 56, 79%), often with sclerodermal changes (n= 21/56, 38%). The second most common indication was GVHD of the liver (n= 21, 30%), followed by pulmonary GVHD in the form of bronchiolitis obliterans (n= 11, 15%), oral (n= 9, 13%), ocular (n= 6, 8%) and GI (n= 3, 4%) GVHD.
Response to Treatment
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The overall response rate was 61% (n= 43), and complete responses were seen in 14 patients. The cumulative incidence of CR/PR at 1 year since initiation of ECP was 83% (SE 9). The best responses were observed in GVHD of the skin, liver, oral mucosa and eye. A total of 33 patients (59%) with skin GVHD responded to ECP therapy, and about half of these responses were seen in patients with sclerodermal forms (n= 14, 42%). Indeed, the majority of patients with scleroderma (n= 14/21, 67%) had objective responses to ECP.
Responses were also seen in liver (n= 15, 71%), oral mucosa (n= 7, 
Mortality
A total of 42 patients (59%) died, with a median follow up of 34 months (4-66 months) among survivors. At 5 years after initiation of ECP, the overall survival was 19% (2-49%), and the cumulative incidence of non-relapse mortality (NRM) was 46% (SE 7) (Fig 1) . The primary cause of death was GVHD plus infection (n= 28, 67%), followed by relapse (n= 12, 29%), infection outside the setting of GVHD or its treatment (n= 1, 2%) and hemorrhage (n= 1, 2%).
Prior Therapy and Outcomes
We stratified patients in 2 groups according to number of therapies preceding ECP, in order to better understand the effects of ECP
Patients who received more than three lines of immunosuppression (n= 8/71) were considered to be heavily pretreated, and were compared to those who received up to 3 lines of immunosuppression including calcineurin inhibitors and steroids (n= 63/71). The cumulative incidence of response was similar in both groups (87% versus 84% respectively). However, the cumulative incidence of progression after responding to ECP was 100 % in the more heavily pretreated group compared to 22% in patients who received up to 3 lines of immunosuppression. Only 1/8 heavily pretreated patients could taper off all immunosuppression, including steroids. In the less pretreated group, the cumulative incidence of complete immunosuppression discontinuation at 1 year after initiation of ECP was 10% (n= 6) and that of steroid discontinuation was 22% (n= 13).
Nonrelapse mortality in the heavily pretreated group was 50% (n= 4) and not significantly different compared to the less immunosuppressed group (41% (n= 26)) (HR 0.7, p= 0.4). The median survival since ECP was 6 months for the heavily pretreated 
Factors Affecting Response and Survival
Patients receiving multiple lines of immunosuppression had a mortality rate of 87% at 19 months since initiation of ECP and only one patient was alive beyond 19 months. The high mortality rate prevented an accurate assessment of the individual prognostic factors that will influence those effects. In addition, the potentially shorter median survival of these patients precludes the analysis of effects that occur over long time periods, such as immunosuppression withdrawal.
Thus, our analysis of factors affecting response and mortality was done on the 63 patients receiving up to 3 lines of immunosuppression.
A platelet count of <100,000/mm3 at time of initiation of ECP was associated with a lower response rate (HR= 0.3, 95% CI 0.1-0.95, p= 0.04). There was a trend towards a higher response rate in patients with LDH levels <1000 IU/L, and in patients with de novo chronic GVHD when compared with progressive and relapsing forms (HR= 2.8, 95% CI 0.8-10.1, p= 0.1). Age, gender, number of prior For personal use only. on October 3, 2017. by guest www.bloodjournal.org From treatments, scleroderma versus other skin disease and HLA compatibility did not significantly impact the response rate (Table 2) .
Several factors that significantly impacted on non-relapse mortality (NRM) are summarized on Table 3 . Response to ECP and platelet count at initiation of therapy were the strongest predictors of NRM on univariate analysis. Less immunosuppressive therapy (2 versus 3 lines, including tacrolimus and steroids), a lower LDH, sclerodermal GVHD and de novo chronic GVHD (versus progressive forms) were also significantly associated to a lower NRM. Of note, de novo chronic GVHD was associated with several factors conferring a more favorable prognosis, including: better response to ECP, less immunosuppressive therapy prior to ECP, sclerodermal forms and a trend to higher platelet counts and lower LDH (Table 4 ).
Patients with de novo chronic GVHD also had a significantly longer median time from diagnosis of chronic GVHD to initiation of ECP, possibly reflecting milder forms of disease with a delayed need for immediate intervention. Since the small sample size precluded multivariate analysis, we evaluated the independent effects of these factors in the subset of patients without de novo chronic GVHD (n= Conversely, patients with thrombocytopenia who achieved a CR or PR with ECP had a lower NRM, although this was not statistically significant (p= 0.4).
Discussion
Chronic GVHD is one of the major limitations to successful allogeneic transplantation, with a substantial impact not only survival but also the quality of life of otherwise cancer-free patients.
Chronic GVHD is a multifaceted disease, and its diagnosis, definition, staging and therefore criteria to evaluate response to therapy are For personal use only. on October 3, 2017. by guest www.bloodjournal.org From particularly challenging. Furthermore, almost every study on chronic GVHD has defined chronic GVHD chronologically (i.e. GVHD beyond day 100), which can result in the misclassification of patients with clinical features of acute GVHD occurring after day 100 as having chronic GVHD [4] . This further complicates evaluation of interventions like ECP [18] , where factors like technical issues, dose (i.e. number of weekly or biweekly treatments), total duration of therapy and criteria for additional salvage immunosuppression after initiation of ECP usually varies from one transplant physician to the other. All these differences need to be taken into account when assessing and comparing the efficacy of this and any therapy for chronic GVHD. and responses up to 80% in skin, 70% in liver and all of the patients with involvement of the oral mucosa [11] . Cases with skin GVHD included sclerodermatous forms with improvement in contractures.
Responses in ulcerative chronic GVHD of the oral mucosa showed resolution in 100% of patients. The procedure was well tolerated, and no major toxicities were reported in this study. Apisarnthanarax et al reported on 32 heavily pretreated patients with chronic GVHD of the skin, with responses in both lichenoid and sclerodermal forms in about half of the patients (CR 22%, PR 34%). The procedure was also well tolerated in this group of patients [15] . There are several other reports on the efficacy of ECP for the treatment of chronic GVHD in small groups of patients, with overall response rates of 50% and higher in skin, oral, eye, liver, GI and also lung GVHD [12, 13, 16] . A similar response rate and tolerability was observed in children with skin and visceral GVHD [14, 19] . All of these reports included patients who had 
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chronic GVHD as well as the biologic effects of ECP on this process.
Massive induction of lymphocyte apoptosis [20, 24] , changes in dendritic cell differentiation and function [21] , induction of regulatory T-cell subsets synthesizing IL-10 [28] and, in the long term, restoration of the DC1/DC2 and Th1/Th2 balance in favor of DC2/Th2 [21, 25] in the course of the disease are some of the proposed mechanisms of action of ECP.
In this retrospective experience, patients were assessed by defined criteria for the diagnosis of chronic GVHD and response to therapy. All patients were diagnosed with chronic GVHD based on a clinical definition and were treated with at least 2 prior lines of immunosuppressive therapy, which included corticosteroids.
Responses were not only seen in chronic GVHD of the skin, but in cases of visceral involvement as well. Most patients with skin GVHD had sclerodermatous involvement, and the majority of these had responses manifested by improved skin scores and/or range of motion in affected joints. Of note, challenging situations such as liver and lung GVHD, showed objective responses in over half of the patients.
Response to ECP, along with thrombocytopenia were the most important prognostic factors affecting NRM. High LDH levels were correlated with both NRM and platelet count, and its significance and value as an independent predictor of survival is unclear. Less immunosuppressive therapy prior to ECP was associated with a trend to a lower NRM as well.
In the small subset of patients who received more than 3 lines of immunosuppression prior to ECP (n= 8), the response rate also was high, but every responder had progression of their chronic GVHD. This group of patients had a relatively short, 18-month median survival after initiation of ECP.
Definitive evaluation of novel therapies for chronic GVHD requires prospective, controlled studies. With some interventions, the benefit of clinical responses was offset by an increase in infectious complications related to immunosuppressive treatment [29] . ECP has activity to improve the symptomatic manifestations of chronic GVHD.
Unfortunately, its prospective evaluation been complicated by a variety of factors including: accessibility to the technique, health insurance coverage, the need for intravenous access and controversies around assessment of chronic GVHD.
Our results warrant further evaluation of ECP in prospective, controlled clinical trials to document its effect on response, survival, immune function, infections and relapse of the underlying disease.
Conclusions
ECP has objective activity in the treatment of chronic GVHD, including in cases of liver and lung GVHD where more objective response parameters were available. The procedure was overall well tolerated, with no fatal toxicities. These results support previous reports of objective responses of skin and visceral GVHD to ECP. Patients who responded to ECP and those with higher platelet counts had a significantly lower NRM, which warrants further studies in earlier stages of chronic GVHD. 
